Dapagliflozin's HFpEF Benefit Recasts HF Treatment: DELIVER

Results from DELIVER made dapagliflozin the third SGLT2 inhibitor to benefit patients with HFpEF, cementing a new, ejection fraction-agnostic management approach.
MDedge News

source https://www.medscape.com/viewarticle/979855?src=rss